Africa’s vast genetic diversity presents a unique opportunity for drug research, yet global science has largely overlooked this potential, says Professor Kelly Chibale of the University of Cape Town. Currently, only 3% of clinical trials are conducted on the continent. Chibale argues for more testing in Africa, stating that it can yield drugs better suited to varied genetic profiles. While he acknowledges that mistrust rooted in colonial and apartheid histories would prevent many on the continent from volunteering for trials, he believes that encouragement from African health experts like himself can make a difference. Chibale emphasizes the importance of local leadership in science, advocating for African institutions to create conducive environments for clinical trials. Successful drug innovation in Africa, he asserts, could drive both health improvements and economic growth, while fostering scientific independence. Chibale develops treatments for diseases affecting African populations, like malaria and tuberculosis, at the H3D research center he founded in 2011.
SOURCE: THE GUARDIAN
